Financings

Cambridge Epigenetix Ltd. raised $21 million in a series B to advance its epigenome sequencing technology.

Corvus Pharmaceuticals Inc. set terms for its IPO, aiming to raise $75 million by selling 4.7 million shares in the $15 to $17 price range and listing on Nasdaq under the ticker CRVS.

Etherna Immunotherapies NV raised $26.6 million in a series A round.

Hutchison China Meditech Ltd. raised $101 million from its IPO of 7.5 million American depositary shares at $13.50 each.

Imprimis Pharmaceuticals Inc. completed a public offering generating net proceeds of approximately $7.4 million.

Deals

ANI Pharmaceuticals Inc. said it will acquire the Inderal LA portfolio from Cranford Pharmaceuticals LLC, which includes the new drug application and trademarks plus the finished goods inventory.

Arch Biopartners Inc. inked an exclusive license agreement with the University of Cincinnati for AB569, a candidate to treat Pseudomonas aeruginosa respiratory infections.

Biota Pharmaceuticals Inc. completed the sale of assets related to its broad spectrum antibiotic program to a newly formed subsidiary of Spero Therapeutics LLC.

Blueprint Medicines Corp. signed a potential $1 billion deal with Roche AG units F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. covering the development of up to five small-molecule drugs targeting kinases deemed important in cancer immunotherapy.

Glaxosmithkline plc and Miltenyi Biotec Inc. formed a strategic collaboration to optimize the manufacturing and delivery of cell and gene therapy-based treatments in oncology and rare diseases.

Janssen Biotech Inc., a unit of Johnson & Johnson, formed a preclinical research alliance with Weill Cornell Medicine to develop new treatment approaches for certain types of cancer.

Ember Therapeutics Inc. acquired ICX-RHY/Vavelta, a regenerative medicine asset, from Intercytex Ltd.

Grünenthal Group entered into a definitive agreement with Almirall Group to acquire 100 percent of the share capital of Almirall de Mexico.

Huya Bioscience International LLC signed an exclusive license with Fudan University for the ex-China rights to a series of novel immuno-oncology drug candidates discovered by Fudan researchers.

Inovio Pharmaceuticals Inc. said it has entered an agreement to acquire all the assets of Bioject Medical Technologies Inc.

Microlin Bio Inc. said that it intends to acquire Marina Biotech Inc.'s nucleic acid therapeutics assets for 6.7 million common shares and about $1 million in cash.

Orexigen Therapeutics Inc. and Takeda Pharmaceuticals USA Inc., a wholly owned subsidiary of Takeda Pharmaceutical Co. Ltd. agreed to terminate their amended and restated collaboration agreement for the weight management drug, Contrave.

Reset Therapeutics Inc. inked a collaboration with an affiliate of Alkermes plc to discover, develop and commercialize orexin receptor modulators from its drug discovery platform.

Scancell Holdings plc signed a research collaboration with scientists in the rheumatology unit at Sweden's Karolinska Institutet to explore the role of citrullinated proteins in the treatment of cancer.

Takeda Pharmaceutical Co. Ltd. and Frazier Healthcare Partners formed Outpost Medicine focused on the development of new treatments of urologic and gynecologic diseases and disorders.

Threshold Pharmaceuticals Inc. terminated the global license and co-development agreement with Merck KGaA for evofosfamide, its hypoxia-activated prodrug of a cytotoxic DNA-alkylating agent.

Vectura Group plc is acquiring Skyepharma plc in a deal that values the firm at $622 million.

Thrombogenics NV signed a global and exclusive license agreement with Galapagos NV to develop and commercialize integrin antagonists for the treatment of diabetic eye disease.

. . . And More

Amgen Inc. said the FDA accepted for review its supplemental biologics license application for Enbrel (etanercept) to treat pediatric patients with chronic severe plaque psoriasis.

Delmar Pharmaceuticals Inc. gained orphan status for its lead product candidate, VAL-083, for the treatment of medulloblastoma.

Shares of GW Pharmaceuticals plc surged more than 130 percent on news that Epidiolex (cannabidiol) met the primary endpoint of a pivotal phase III trial in Dravet syndrome.

Pfizer Inc. said the FDA approved Xalkori (crizotinib) to treat people with advanced non-small-cell lung cancer whose tumors have an ROS-1 gene alternation.

Pronai Therapeutics Inc. said its BCL2-targeting oncology candidate, PNT2258, was granted orphan designation by the FDA for the treatment of diffuse large B-cell lymphoma.